University of Torino

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The new subsidiary will focus on expanding the company's liquid biopsy technology capabilities and growing European adoption of its platform.

The partners will compare Adaptive Bio's clonoSeq MRD test with flow cytometry for accuracy and reliability in monitoring MRD in multiple myeloma patients. 

As research reveals tumor features that can affect circulating tumor DNA levels, investigators are considering several sequencing and PCR-based clinical applications for the bloodstream-borne nucleic acids — from early detection and diagnosis to minimal residual disease monitorin

NEW YORK (GenomeWeb News) – A study in Science Translational Medicine has started cataloguing the characteristics, constraints, and potential clinical applications of circulating tumor DNA.

Horizon Discovery also plans to participate in a consortium of "top academic institutions and big pharmas" in the cancer field, a research partnership expected to expand its panel of isogenic cell lines for drug discovery.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.